This FDC has been launched under the brand name Zita-PioMet, and contains Teneligliptin (20 mg) + Pioglitazone (15 mg) + Metformin (500mg/1000mg) in a sustained release (SR) formulation
As per 10th edition of International Diabetes Federation (IDF) Atlas, 2021, India has 74.2 million people with diabetes between the age of 20-79 years
To fund the upfront payment, Biocon Biologics has secured USD 1.2 billion of Sustainability Linked Loan
India is home to nearly 80 million diabetics and this number is expected to rise to a staggering 134 million in the next 25 years.
This is the fifth consecutive year that a Biocon Group company has made it to the Asia lP ELITE list
Gland Pharma Q2 FY2023 consolidated net profit up at Rs. 241.24 Cr
Yoshindo gets exclusive commercialization rights in Japan for bUstekinumab and bDenosumab developed and manufactured by Biocon Biologics
Glenmark is the first company in India to launch Thiazolidinedione Lobeglitazone (0.5 mg).
This includes Madhurodhi, HBP Care & LBP Care for sugar & BP patients
The observations primarily relate to the need for improving strategies for microbial control, enhancing quality oversight, augmenting the use of software applications & computerized tools
Subscribe To Our Newsletter & Stay Updated
